<DOC>
	<DOCNO>NCT00033514</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Biological therapy erlotinib may interfere growth tumor cell slow growth tumor . Combining trastuzumab erlotinib may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine trastuzumab erlotinib first-line therapy treat woman metastatic breast cancer associate HER2/neu overexpression .</brief_summary>
	<brief_title>Trastuzumab Erlotinib First-Line Therapy Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose erlotinib combine trastuzumab ( Herceptin ) first-line therapy woman metastatic breast cancer associate HER2/neu overexpression . ( Phase I close accrual 01/2004 ) - Determine safety profile regimen patient . - Determine rate duration objective response patient treat regimen . - Determine pharmacologic behavior regimen patient . - Determine time disease progression duration survival patient treat regimen . - Correlate antitumor activity regimen epidermal growth factor receptor expression patient . OUTLINE : This dose-escalation study erlotinib . ( Phase I close accrual 01/2004 ) . Patients receive oral erlotinib daily begin day 2 trastuzumab ( Herceptin ) IV 30-90 minute ( 1-4 hour erlotinib ) weekly begin day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat recommended phase II dose . Patients follow every 2 month . PROJECTED ACCRUAL : A total 3-18 patient accrued phase I portion ( close accrual 01/2004 ) 27-81 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women age &gt; 18 year Histologically document metastatic breast cancer HER2 positive use FISH For phase I , patient previously receive treatment metastatic disease allow participate . For phase II portion study , patient must measureable disease ( &gt; 2 cm ; &gt; 1 cm spiral CT scan ) ECOG performance status 0 2 A life expectancy &gt; 3 month Use effective mean contraception For Phase II , prior cytotoxic chemotherapy and/or prior Herceptin metastatic disease . Prior treatment adjuvant setting allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>